[{"notes_id":"1_855","category":"6","subcategory":"2","title":"Methotrexate","body":"Methotrexate is an antimetabolite that <span class=\"concept\" data-cid=\"7978\">inhibits dihydrofolate reductase<\/span>, an enzyme essential for the synthesis of purines and pyrimidines. It is considered an 'important' drug as whilst it can be very effective in controlling disease the side-effects may be potentially life-threatening - careful prescribing and close monitoring is essential.<br \/><br \/>The mechanism of action of methotrexate is complicated and can depend on dose:<br \/><ul><li>core mechanism of action:<ul><li>folate analogue \u2192 competitively inhibits dihydrofolate reductase (DHFR).<\/li><li>this prevents conversion of dihydrofolate \u2192 tetrahydrofolate, which is essential for purine and thymidylate synthesis.<\/li><li>result = \u2193 DNA and RNA synthesis, especially in rapidly dividing cells.<\/li><\/ul><\/li><li>at low weekly doses (rheumatology, e.g. rheumatoid arthritis, psoriasis):<ul><li>immunomodulatory effect is more important than direct cytotoxicity.<\/li><li>inhibits AICAR transformylase \u2192 <span class=\"concept\" data-cid=\"12486\">accumulation of adenosine<\/span>, a potent anti-inflammatory mediator.<\/li><li>suppresses T-cell activation and cytokine production.<\/li><li>reduces proliferation of lymphocytes in synovium\/skin.<\/li><\/ul><\/li><li>at high doses (oncology use)<ul><li>anti-proliferative \/ cytotoxic effect<\/li><li>direct inhibition of nucleotide synthesis \u2192 apoptosis of rapidly dividing malignant cells.<\/li><li>often given with folinic acid (leucovorin) rescue to protect normal tissues.<\/li><\/ul><\/li><\/ul><br \/>Indications<br \/><ul><li>inflammatory arthritis, especially <span class=\"concept\" data-cid=\"7979\">rheumatoid arthritis<\/span><\/li><li>psoriasis<\/li><li>some chemotherapy acute lymphoblastic leukaemia<\/li><\/ul><br \/>Adverse effects<br \/><ul><li><span class=\"concept\" data-cid=\"8269\">mucositis<\/span><\/li><li><span class=\"concept\" data-cid=\"8270\">myelosuppression<\/span><\/li><li><span class=\"concept\" data-cid=\"8271\">pneumonitis<\/span><ul><li>the most common pulmonary manifestation<\/li><li>similar disease pattern to hypersensitivity pneumonitis secondary to inhaled organic antigens<\/li><li>typically develops within a year of starting treatment, either acutely or subacutely<\/li><li>presents with non-productive cough, dyspnoea, malaise, fever<\/li><\/ul><\/li><li><span class=\"concept\" data-cid=\"8272\">liver fibrosis<\/span><\/li><\/ul><br \/>Whilst methotrexate was previously thought to cause pulmonary fibrosis recent longer term follow up studies do not support this association.<br \/><br \/>Pregnancy<br \/><ul><li>women should avoid pregnancy for at least <span class=\"concept\" data-cid=\"991\">6 months<\/span> after treatment has stopped<\/li><li>the BNF also advises that men using methotrexate need to use effective contraception for at least <span class=\"concept\" data-cid=\"991\">6 months<\/span> after treatment<\/li><\/ul><br \/>Prescribing methotrexate<br \/><ul><li>methotrexate is a drug with a high potential for patient harm. It is therefore important that you are familiar with guidelines relating to its use<\/li><li><span class=\"concept\" data-cid=\"10615\">methotrexate is taken weekly, rather than daily<\/span><\/li><li>FBC, U&E and LFTs need to be regularly monitored. The Committee on Safety of Medicines recommend 'FBC and renal and LFTs before starting treatment and repeated weekly until therapy stabilised, thereafter patients should be monitored every 2-3 months'<\/li><li><span class=\"concept\" data-cid=\"9728\">folic acid 5mg once weekly should be co-prescribed<\/span>, taken more than 24 hours after methotrexate dose<\/li><li>the starting dose of methotrexate is 7.5 mg weekly (source: BNF)<\/li><li>only one strength of methotrexate tablet should be prescribed (usually 2.5 mg)<\/li><\/ul><br \/>Interactions<br \/><ul><li>avoid prescribing <span class=\"concept\" data-cid=\"894\">trimethoprim<\/span> or <span class=\"concept\" data-cid=\"3187\">co-trimoxazole<\/span> concurrently - increases risk of marrow aplasia<\/li><li>high-dose <span class=\"concept\" data-cid=\"4323\">aspirin<\/span> increases the risk of methotrexate toxicity secondary to reduced excretion<\/li><\/ul><br \/>Methotrexate toxicity<br \/><ul><li>the treatment of choice is <span class=\"concept\" data-cid=\"2237\">folinic acid<\/span><\/li><\/ul>","notes_hash":"aace10f73ed0b08040942ffd965dbb26","knowledge_graph_node_id_link":10626,"links":"<table style='width:100%'><tr><td>British Society for Rheumatology<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1423\" data-linkid=\"1423\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1423\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">10<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1423\" data-linkid=\"1423\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1423\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">8<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/academic.oup.com\/rheumatology\/article\/56\/6\/865\/3053478\">2017 Guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>British Association of Dermatologists<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1582\" data-linkid=\"1582\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1582\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">11<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1582\" data-linkid=\"1582\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1582\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">8<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/bjd.14816\">2016 Guidelines for the safe and effective prescribing of methotrexate for skin disease<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>BNF<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1220\" data-linkid=\"1220\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1220\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">16<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1220\" data-linkid=\"1220\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1220\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">8<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/bnf.nice.org.uk\/drug\/methotrexate.html\">Methotrexate<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/2k4-NuFjto0\" data-description=\"Methotrexate - Pharmacology (DMARDs, mechanism of action, side effects)\" data-upvotes=\"5\" data-downvotes=\"4\" data-media=\"1111\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/2k4-NuFjto0\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/2k4-NuFjto0\" data-description=\"Methotrexate - Pharmacology (DMARDs, mechanism of action, side effects)\" data-upvotes=\"5\" data-downvotes=\"4\" data-media=\"1111\">Methotrexate - Pharmacology (DMARDs, mechanism of action, side effects)<\/a><\/td><\/tr><tr><td><span ><small>Armando Hasudungan - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1924\" data-mediaid=\"1924\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1924\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">5<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1924\" data-mediaid=\"1924\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1924\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">4<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"894":{"concept_text":"The concurrent use of methotrexate and trimethoprim containing antibiotics may cause bone marrow suppression and severe or fatal pancytopaenia","concept_percentile":"71"},"3187":{"concept_text":"Co-trimoxazole contains trimethoprim and therefore should never be prescribed with methotrexate","concept_percentile":"92"},"8269":{"concept_text":"Methotrexate may cause mucositis","concept_percentile":"14"},"8270":{"concept_text":"Methotrexate may cause myelosuppression\/agranulocytosis","concept_percentile":"39"},"8271":{"concept_text":"Methotrexate may cause pneumonitis - typically presents with cough, dyspnoea and fever","concept_percentile":"50"},"8272":{"concept_text":"Methotrexate may cause hepatotoxicity - monitor LFTs","concept_percentile":"32"}},"category_name":"Musculoskeletal","subcategory_name":"Rheumatology","comment_count":8},"",[]]